Company Overview of DNAtrix, Inc.
DNAtrix, Inc., a clinical stage biotechnology company, develops virus-driven immunotherapies for cancer. It offers DNX-2401, an oncolytic immunotherapy for glioblastoma; DNX-2440 and DNX-2450, which are armed DNX virus in development for solid tumors; and MYX-135, an oncolytic immunotherapy that is designed to treat hematological malignancies. DNAtrix, Inc. was incorporated in 2005 and is based in Houston, Texas.
2450 Holcombe Boulevard
Suite X+ 200
Houston, TX 77021
Founded in 2005
Key Executives for DNAtrix, Inc.
Chief Executive Officer and Director
Compensation as of Fiscal Year 2016.
DNAtrix, Inc. Key Developments
DNAtrix Therapeutics Receives Orphan-Medicine Designation for Oncolytic Immunotherapy Candidate DNX-2401 from European Commission
Feb 11 16
DNAtrix Therapeutics has secured an orphan-drug designation from the European Commission for its oncolytic immunotherapy candidate DNX-2401. DNX-2401 is a conditionally replicative oncolytic adenovirus designed to target cells defective in the retinoblastoma (Rb) pathway, which is present in many cancers. The lead DNAtrix product candidate received dual fast-track and orphan status from the US FDA in October 2014. The drug is being investigated as a potential treatment option for glioblastoma, a brain tumour that is resistant to conventional therapies. An average of about 25,000 patients is diagnosed with glioblastoma per annum in the United States and Europe. The decision by European regulators to confer orphan status on DNAtrix will allow the US firm to avail of significant regulatory benefits and incentives in terms of reduced fees, scientific advice, and the possibility of securing a 10-year period of market exclusivity, assuming that DNX-2401 is eventually cleared for market authorisation in Europe in the designated indication. DNAtrix has recently completed enrolling patients with recurrent high-grade gliomas for a Phase Ib clinical study in Spain, and is planning a separate European study in newly diagnosed cases in 2016. Merck & Co entered into a research agreement with DNAtrix in October 2015 to evaluate Merck's PD-1 inhibitor Keytruda (pembrolizumab) with DNX-2401 in Phase II trials. The orphan-drug designation for DNX-2401 is considered a promising development for DNAtrix Therapeutics. Securing the designation is not a guarantee that the experimental therapy will prove successful in later-stage safety and efficiency studies. However, the company will be entitled to regulatory benefits, ranging from protocol assistance and reduced fees for regulatory approval in the European Union. This may potentially accelerate the time to market for the drug.
Merck & Company Collaborates with DNAtrix to Study DNX-2401, Keytruda in Glioblastoma
Oct 1 15
Merck & Company has entered into a collaboration with DNAtrix for an oncology clinical study collaboration to evaluate the efficacy and safety of DNX-2401, DNAtrix's oncolytic immunotherapy in combination with Keytruda. The phase 2 study will be on patients with recurrent glioblastoma, the most aggressive form of brain cancer for which there is no cure.
DNAtriX, Inc. Presents at Leerink Partners Immuno-Oncology Roundtable, Oct-01-2015 02:20 PM
Sep 25 15
DNAtriX, Inc. Presents at Leerink Partners Immuno-Oncology Roundtable, Oct-01-2015 02:20 PM. Venue: Le Parker Meridien Hotel, New York, New York, United States. Speakers: Frank Tufaro, Chief Executive Officer and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|